Efectos de la suspensión de IECA y ARAII en enfermedad crónica avanzada

Díaz-Domínguez, Martha E; Fernández-Lucas, Milagros; Gomis-Couto, Antonio; Ruiz-Roso, Gloria; Teruel, José L; Quereda, Carlos.
Nefrología (Madr.) ; 32(3): 400-401, mayo-jun. 2012. tab
Artículo en Español | IBECS (España) | ID: ibc-103383

Documentos relacionados

  1. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
  2. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
  3. Management of heart failure in patients with kidney disease-updates from the 2021 ESC guidelines.
  4. Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
  5. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.
  6. Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.
  7. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.
  8. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis.
  9. Comparative risk of new-onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A Bayesian network meta-analysis.
  10. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.